# Study of the Safety and Leukostimulatory Activity of the Preparation "Panagen" in Patients With Breast Cancer

> **NCT02115984** · PHASE2 · COMPLETED · sponsor: **Panagen, Limited Liability Company** · enrollment: 80 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Panagen
- **DRUG:** Placebo
- **PROCEDURE:** Chemotherapy

## Key facts

- **NCT ID:** NCT02115984
- **Lead sponsor:** Panagen, Limited Liability Company
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2014-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115984, "Study of the Safety and Leukostimulatory Activity of the Preparation "Panagen" in Patients With Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02115984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*